StockNews.AI
KURA
StockNews.AI
117 days

Kura Oncology to Report First Quarter 2025 Financial Results

1. Kura will report Q1 2025 results on May 1, 2025. 2. Ziftomenib is first oral menin inhibitor with Breakthrough Therapy Designation. 3. NDA submission for ziftomenib is expected in Q2 2025. 4. KO-2806 is being tested in Phase 1 trials for solid tumors. 5. Ziftomenib is part of a collaboration with Kyowa Kirin.

Earnings
+1.33%Current Return
VS
+2.52%S&P 500
$6.3704/24 07:36 AM EDTEvent Start
$6.45504/25 02:15 PM EDTLatest Updated
5m saved
Insight
Article

FAQ

Why Bullish?

Kura's advancements, particularly with ziftomenib in AML, indicate promising future earnings. Historical responses to drug approvals often lead to stock increases.

How important is it?

The announcement directly relates to key product milestones, influencing investor sentiment and stock price.

Why Short Term?

The upcoming earnings report and NDA submission create immediate investor interest and potential volatility.

Related Companies

KYKRNAMGNGILD
April 24, 2025 07:30 ET  | Source: Kura Oncology, Inc. SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report first quarter 2025 financial results after the close of U.S. financial markets on Thursday, May 1, 2025. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the financial results and provide a corporate update. The live call may be accessed by dialing (800) 245-3047 for domestic callers and (203) 518-9765 for international callers and entering the conference ID: KURAQ1. A live webcast and archived replay of the event will be available here or online from the investor relations section of the company website at www.kuraoncology.com. About Kura Oncology Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates, designed to target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food & Drug Administration for the treatment of relapsed/refractory (R/R) NPM1-mutant (NPM1-m) AML. In November 2024, Kura entered into a global strategic collaboration agreement with Kyowa Kirin to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-m AML has been completed, and in the second quarter of 2025, the companies announced submission of an NDA for ziftomenib for the treatment of adult patients with R/R NPM1-m AML. Kura and Kyowa Kirin are conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-m and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor (FTI), is being evaluated in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with targeted therapies for patients with various solid tumors. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura’s website at https://kuraoncology.com/ and follow us on X and LinkedIn. Contacts Investors:Patti BankManaging Director(415) 513-1284patti.bank@icrhealthcare.com Media:Alexandra WeingartenAssociate Director, Corporate Communications & Investor Relations(858) 500-8822alexandra@kuraoncology.com

Related News